NATURAL HISTORY OF RARE GENETIC STEROID DISORDERS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 描述(由申请人提供)：一个由研究人员、机构和患者支持团体组成的联盟将组成一个罕见疾病临床研究网络，专注于以类固醇合成缺陷为特征的不同疾病组。我们将研究这些罕见疾病的纵向病史，并确定身高、生育能力和性别的治疗结果。威尔医学院、洛克菲勒大学、哥伦比亚大学、德克萨斯大学西南医学中心、魁北克大学、德布罗西斯医院(里昂)和圣保罗诊所(圣保罗)的研究人员之间的长期非正式合作将有助于建立一个富有成效的合作研究网络，利用每个研究人员的丰富经验。位于洛克菲勒韦尔的临床研究中心和德克萨斯大学西南医学中心将参与其中。该联盟中的每一名研究人员多年来跟踪了一大群具有影响类固醇合成的特定基因缺陷的患者，涵盖了这些疾病从产前到死亡的自然历史。存储和管理数据库的创建将构成正在进行的研究的脚手架，使得能够保存和使用由每种疾病的专家收集的大量临床数据。此外，为这些疾病的标准化临床描述设计模板将允许进行前瞻性研究，这些研究可以为受影响的个人或处于风险中的个人提供公开登记。我们的研究小组包括研究人员，他们已经确定了每种疾病的分子遗传缺陷，如果已知，并拥有致力于识别新突变的实验室。临床和分子遗传信息的结合将提高医疗保健的标准，并可能基于对这些疾病的自然历史和分子遗传学基础的详细知识开发新的治疗方法。我们计划的重要内容是(1)建立临床研究网络，与DTCC合作汇集我们网站的数据并分析这些数据，(2)教育年轻研究人员类固醇紊乱的管理和临床研究，以及(3)加强我们与患者支持团体的联系，使受影响或有风险的个人能够获得新的投入和获得最佳医疗护理

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. DESCRIPTION (provided by applicant): A consortium of investigators, institutions, and patient support groups will constitute a Rare Disease Clinical Research Network focused on a diverse group of disorders characterized by defects in steroidogenesis. We will study the longitudinal history of these rare disorders and determine the outcome of treatment on height, fertility and gender. Long-standing informal collaboration between investigators at Weill Medical College, Rockefeller University, Columbia University, the University of Texas Southwestern Medical Center, the University of Quebec, Hospital Debrosses (Lyons), and the Hospital das Clinicas da FMUSP (Sao Paulo) will facilitate the creation of a productive cooperative research network that draws on the extensive experience of each investigator. Clinical Research Centers at Weill, Rockefeller, and the University of Texas Southwestern Medical Center will participate. Each investigator in the consortium has followed a large group of patients with a specific genetic defect affecting steroid synthesis over many years, encompassing the natural history of these diseases from prenatal life to death. Creation of a storage and management database will constitute a scaffold for ongoing research, enabling the preservation and use of this large body of clinical data assembled by experts in each disorder. Moreover, design of templates for a standardized clinical description of these disorders will permit prospective studies which can offer open enrollment to affected individuals or individuals at risk. Our research group includes the investigators who have identified the molecular genetic defect for each disorder, where known, and who maintain laboratories dedicated to the identification of new mutations. The combination of clinical and molecular genetic information will raise the standard of medical care and may permit development of novel treatments based on detailed knowledge of the natural history and molecular genetic basis of these disorders. Important elements of our plan are (1) to establish the clinical research network which pools data from our sites in cooperation with the DTCC and analyzes this data, (2) to educate young investigators in the management and clinical research of steroid disorders, and (3) to strengthen our connections with patient support groups to enable individuals affected or at risk to have new kinds of input and access to optimal medical care